ABUS

Arbutus Biopharma Corporation
CAPPED RATING

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Vancouver, British Columbia and has research facilities in Warminster, Pennsylvania.

Arbutus Biopharma Corporation (ABUS) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Growth (F). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B
Factor Score 3.4 / 5.0
Growth
F
Factor Score 0.5 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 3.6
EV / EBITDA 2.0
Rev Growth YoY -43.5%
Gross Margin 91.9%
Price Return 3M -16.5%
Price Return 12M -11.4%
Catalyst Signal 0.00
Market Cap $619.3M
TTM Revenue $181.5M
Price / Sales 3.4
ROE 269.6%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.4) F (0.5) B+ (3.8) C+ (2.7) C+ (2.6) C+ (2.6)
2026-11-10 B (3.4) F (0.2) B+ (3.7) C+ (2.5) C+ (2.6) C+ (2.5)
2026-11-03 B (3.4) F (0.2) B+ (3.7) C+ (2.8) C+ (2.7) C+ (2.6)
2026-10-27 B (3.4) F (0.2) B+ (3.8) B- (2.9) C+ (2.6) C+ (2.6)
2026-10-20 B (3.4) F (0.2) B+ (3.8) C+ (2.8) C+ (2.6) C+ (2.6)
Page 1 of 8
…